|

Retinal Imaging in Neurodegenerative Disease

RECRUITINGSponsored by Duke University
Actively Recruiting
SponsorDuke University
Started2017-07-20
Est. completion2026-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site

Summary

This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD), or other neurodegenerative disease, diseases as outlined.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adults with neurodegenerative disease ((MCI, PD, AD, FTD, DLB, ALS, MS, HD, TBI, concussion, PTSD and other neurodegenerations as well as Down Syndrome)
* Adults without neurodegenerative disease

Exclusion Criteria:

* Inability to cooperate with or complete testing or other neurologic or age- related ocular conditions that would impact image acquisition.
* Eyes that have had intraocular surgery, other than cataract surgery.

If two eyes satisfy the inclusion criteria, both eyes will be included in the study. If one eye satisfies the inclusion criteria, the eye that qualifies will be included in the study.

Conditions15

APOE-4 PositiveAlzheimer's DiseaseAmyotrophic Lateral Sclerosis (ALS)ConcussionDown SyndromeFrontotemporal DementiaHuntington DiseaseLewy Body DementiaMild Cognitive ImpairmentMultiple Sclerosis

Locations1 site

Duke University Medical Center
Durham, North Carolina, 27705
Sharon Fekrat, MD FACS FASRS919-681-3937imind@duke.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.